Halozyme Therapeutics (NASDAQ:HALO) Announces Quarterly Earnings Results, Misses Expectations By $2.16 EPS

Halozyme Therapeutics (NASDAQ:HALO) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16), FiscalAI reports. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. During the same quarter in the previous year, the company posted $1.26 EPS. The firm’s revenue was up 51.6% on a year-over-year basis.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Halozyme reported a record $1.4 billion in 2025 revenue (up 38%) and $868M in royalty revenue (up 52%), driven mainly by ENHANZE-enabled blockbusters DARZALEX SC, Phesgo and VYVGART Hytrulo.
• The company broadened its subcutaneous delivery portfolio by acquiring Elektrofi’s Hypercon and Surf Bio’s hyperconcentration technologies (IP into the mid‑2040s), positioning Halozyme as a one‑stop shop and targeting ~36 combined commercial/development products by 2028.
• Preclinical data indicate ENHANZE may enable safe subcutaneous delivery of antibody‑drug conjugates with much lower Cmax and similar or higher overall exposure, a finding that could materially expand ENHANZE’s addressable modalities if confirmed clinically.
• Management reiterated strong 2026 guidance (total revenue $1.71–$1.81B; royalty revenue $1.13–$1.17B; non‑GAAP EPS $7.75–$8.25) and highlighted balance‑sheet moves (new convertible notes, repurchases, larger revolver) with a plan to delever below 1x net debt/EBITDA by end‑2026.
• Legal and IP risk remains — an IPR involving Alteogen and an active district‑court infringement case (involving Merck) are ongoing, with discovery permitted, creating potential litigation uncertainty for the company.

Halozyme Therapeutics Stock Up 1.3%

Shares of NASDAQ:HALO traded up $1.04 on Tuesday, reaching $80.48. The company had a trading volume of 2,101,709 shares, compared to its average volume of 1,978,029. The firm has a market capitalization of $9.46 billion, a PE ratio of 16.94, a PEG ratio of 0.33 and a beta of 0.97. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics has a 52-week low of $47.50 and a 52-week high of $82.22. The firm’s 50 day simple moving average is $71.55 and its 200-day simple moving average is $70.25.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the transaction, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00. Following the sale, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at $55,733,662.16. The trade was a 1.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 49,398 shares of company stock worth $3,650,592. 2.90% of the stock is owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new position in Halozyme Therapeutics during the 4th quarter valued at approximately $114,000. Aster Capital Management DIFC Ltd lifted its holdings in shares of Halozyme Therapeutics by 40.7% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 2,566 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 742 shares during the period. Integrated Quantitative Investments LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $210,000. CIBC Private Wealth Group LLC grew its position in Halozyme Therapeutics by 12.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,891 shares of the biopharmaceutical company’s stock worth $212,000 after purchasing an additional 329 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in Halozyme Therapeutics by 919.0% during the second quarter. Daiwa Securities Group Inc. now owns 4,025 shares of the biopharmaceutical company’s stock valued at $209,000 after acquiring an additional 3,630 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Reported record full‑year 2025 total revenue of $1.397B and reiterated 2026 guidance with strong growth ranges (2026 total revenue $1.71–$1.81B; adjusted EBITDA $1.125–$1.205B; non‑GAAP EPS $7.75–$8.25), which supports revenue visibility and margin expansion expectations. PR Newswire Release
• Positive Sentiment: Fourth‑quarter revenue came in at roughly $452M, up ~52% year‑over‑year and slightly above consensus, underscoring continued strength in the ENHANZE royalties and partner revenue streams. Quiver Quant
• Neutral Sentiment: Street sentiment remains broadly constructive (consensus “Moderate Buy” / median price target ~$84.5) though analyst targets vary widely — a mixed analyst backdrop that can mute extreme moves. Quiver Quant (analyst notes)
• Neutral Sentiment: Educational/momentum coverage and retrospectives (e.g., Zacks, MSN/Benzinga previews) may attract momentum and retail interest but are less likely to move the stock materially versus the company’s fundamentals and guidance. Zacks Momentum Piece
• Negative Sentiment: Reported EPS missed consensus (quarterly EPS reported at a loss versus higher analyst expectations) and the company recorded a larger operating and net loss in the quarter, which triggered near‑term selling pressure after the release. MarketBeat Earnings Summary
• Negative Sentiment: Quiver highlights a significant year‑over‑year rise in operating loss and liabilities, plus heavy insider stock sales (multiple executives sold shares recently), which can concern investors about near‑term dilution or sentiment. Quiver Quant (financials & insider activity)

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Morgan Stanley cut their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a report on Monday, October 20th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. The Goldman Sachs Group reiterated a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Finally, TD Cowen raised their price objective on Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $77.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.